Table 1 FLIM-FRET parameters predictors of doxorubicin drug response in PCa cell lines.
FLIM parameters/Molecular Targets | Molecular Changes in LNCaP & E006AA Doxorubicin Rx in “Pre-Apoptotic” Phase (0–60 min) | Molecular changes in LNCaPs Cells Doxorubicin “Responsive” (~24 hr) | Molecular changes in E006AA Cells Doxorubicin “Slow Responders” (~24 hr) |
|---|---|---|---|
NAD(P)H-τm | Increases | Increases | Increases |
NAD(P)H-a2% | Increases | Increases | Increases |
FAD-a1% | Decreases | Decreases | Decreases |
NAD(P)H-a2%/FAD-a1% FLIM Redox Ratio | Increases | Increases | Increases |
E% vs NAD(P)H-a2%/FAD-a1% Correlation | Increases | Decreases | No Change |
